OncoKB 地址： https://oncokb.org/ Paper ： https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540/pdf/nihms897314.pdf https://ascopubs.org/doi/pdfdirect/10.1200/PO.17.00011
OncoKB （Oncology Knowledge Base），是由MSK（Memorial Sloan Kettering）癌症中心维护的全面的精准医疗肿瘤数据库。这个数据库旨在提供一些详细的、基于证据关于somatic突变和结构突变的信息，从而帮助进行治疗决策。数据基于FDA （US Food and Drug Administration ）, NCCN（National Comprehensive Cancer Network ) 的资料以及其他文献，和疾病专家小组的建议对药物反应做证据分类。这个数据库现在每隔2-3个月进行一次更新和补充。现在已经有4932个突变，涉及642个基因，45种肿瘤，89种药物。
Level 3A includes mutations that are candidate predictive biomarkers of drug response based on off-label use of FDA-approved drugs or investigational agents not yet FDA-approved for any indication.
Level 2A includes alterations that are not FDA-recognized biomarkers, but are considered standard care predictive biomarkers of response to an FDA-approved therapy in specific cancer types.
Level 3A includes mutations that are candidate predictive biomarkers of drug response based on off-label use of FDA-approved drugs or investigational agents not yet FDA-approved for any indication.
Level 4 alterations are candidate predictive biomarkers of response to either FDA-approved or investigational agents based on compelling laboratory data and an absence of substantiating compelling clinical data.
OncoKB classifies mutations that have been shown to confer resistance to specific targeted therapies into one of three levels based upon the strength of the evidence that the mutation is predictive of treatment resistance
